The Clinical Challenge of Predicting and Preventing Sudden Cardiac Death  Immediately after Myocardial Infarction by Estes III, N.A. Mark
The Clinical Challenge of Predicting 
and Preventing Sudden Cardiac Death 
Immediately after Myocardial Infarction
N.A. Mark Estes III, MD
A B S T R A C T
Despite many advances in treatment of myocardial infarction (MI) with percutane-
ous coronary intervention (PCI) and pharmacologic therapies, mortality immediately 
after MI remains high in patients with impaired left ventricular function. One of the 
greatest challenges facing the contemporary cardiologist is predicting and preventing 
sudden cardiac death (SCD) immediately after MI. Unfortunately, the trials assessing 
the role of the implantable cardioverter defibrillator (ICD) in patients at high risk 
for SCD immediately post MI have failed to show survival benefit. Current clinical 
guidelines restrict ICD implants to patients at least 40 days after MI with continued 
left ventricular dysfunction while on optimal medical therapy. It is evident that ad-
ditional research is needed to identify strategies to prevent SCD and improve survival 
immediately after MI. In the meantime, clinicians should optimize and individualize 
therapy in the immediate post MI patient while carefully considering the risk of SCD 
and the competing risk of mortality from other causes.
One of the greatest challenges facing the contemporary cardiologist is predicting 
and preventing sudden cardiac death (SCD) immediately after myocardial infarction 
(MI).1,2 Despite many advances in treatment of ST segment elevation MI (STEMI) 
with percutaneous coronary intervention (PCI) and pharmacologic therapies, mortality 
immediately after STEMI remains high in patients with impaired left ventricular ejec-
tion fraction (LVEF). In this patient population there is a disproportionately high risk 
of sudden death relative to total mortality.3,4 Despite optimal therapy, the risk of SCD 
is highest in the few months post MI among patients with left ventricular dysfunction.4 
It is evident that early implementation of strategies for prevention of sudden death 
immediately after a STEMI are essential to improve total mortality.
Both invasive and noninvasive risk stratification techniques have been evaluated in 
an effort to identify individuals at high risk of SCD after STEMI.5 Risk stratification 
methods should provide information about the ratio of sudden and non-sudden cardiac 
death.5,6 The techniques of risk stratification need to be clinically linked to effective 
pharmacologic or nonpharmacologic interventions that prevent SCD and improve 
mortality. 6 Percutaneous coronary intervention (PCI), beta-blockers and angiotensin 
converting enzymes inhibitors improve long-term outcomes in patients after MI. An-
tiarrhythmic agents used to suppress spontaneous or induced arrhythmias have had a 
EDITORIAL
Tufts University School of Medicine, 
Boston, MA, USA
HOSPITAL CHRONICLES 2012, 7(2): 74–76
Correspondence to:
N.A. Mark Estes III, MD
Professor of Medicine
Tufts University School of Medicine
750 Washington Street
Boston, MA 02111, USA
Tel.: 617-636-6156, Fax: 617-636-4586
E-mail: nestes@tuftsmedicalcenter.org
Manuscript received February 27, 2012; 
accepted after revision March 16, 2012
KEY WORDS: sudden cardiac death; 
acute myocardial infarction; left 
ventricular dysfunction; coronary 
artery disease; implantable cardioverter 
defibrillator
ABBREVIATIONS
ICD = implantable cardioverter 
defibrillator 
LVEF = left ventricular ejection fraction 
MI = myocardial infarction 
PCI = percutaneous coronary intervention 
SCD = sudden cardiac death 
STEMI = ST elevation myocardial 
infarction 
Conflict of Interest: none declared
SUDDEN DEATH IMMEDIATELY AFTER MI
75
neutral or negative effect on mortality in this patient popula-
tion.6 While the implantable cardioverter defibrillator (ICD) 
reduces arrhythmic death in patients immediately after MI, it 
has not impacted favorably on total mortality.7,8 
Traditionally the LVEF has been a useful marker of 
increased mortality after MI.6 However, it is not useful for 
identification of patients at increased risk of arrhythmic death 
relative to total mortality.2,6 Among the risk stratification tech-
niques evaluated alone or in conjunction with LVEF to identify 
patients at high risk for arrhythmic mortality are spontaneous 
or induced ventricular arrhythmias and multiple noninvasive 
risk stratification techniques.5 However, neither the invasive 
or noninvasive risk stratification techniques have sufficient 
overall predictive accuracy to improve the ratio of SCD to total 
mortality.2,6 In patients with high rates of sudden death but low 
rates of non-sudden death, ICD therapy can provide effective 
and cost-effective therapy.2,6 However, when used in patients 
with lower ratios of sudden to non-sudden death the benefit 
of therapy is substantially diminished as these patients have 
a high mortality rate even if SCD is effectively prevented.2,6
Multiple clinical trials randomizing several thousand 
patients have demonstrated that the ICD prevents sudden 
death and significantly reduces overall mortality among 
patients with left ventricular dysfunction due to ischemic 
heart disease.2,6 These trials demonstrating a survival benefit 
have excluded patients with recent myocardial infarction.2,6 
However, the trials assessing the role of the ICD in patients 
at high risk for SCD immediately post MI have failed to show 
survival benefit.7,8 The DINAMIT Trial assessed the strategy 
of ICD use in a randomized controlled prospective study of 
674 patients within 4-40 days after an index MI. All enrolled 
were on optimal pharmacologic therapy and had LVEF <35% 
with markers of autonomic dysfunction. Only 27% of patients 
were treated with PCI. While depressed LVEF and low heart 
rate variability identify patients with increased mortality risk, 
the trial did not identify any subsequent benefit from use of 
the ICD in these high risk patients.7
Another clinical trial, the IRIS Trial, evaluated the strategy 
of early post MI ICD implantation with randomization of 900 
high risk patients within one month of an MI. Patients were 
selected based on an LVEF <40% while on optimal medical 
therapy.8 Primary PCI was performed in 245 of these patients. 
While the ICD group showed a significant reduction in the 
arrhythmic mortality, this was offset by an increase in nonar-
rhythmic death, similar to the DINAMIT Trial.7,8
A prospective randomized trial evaluating the strategy of 
home automated external defibrillators use in high risk post 
MI patients also failed to improve survival when compared to 
conventional resuscitation methods.9 While there is a reason-
able rationale for a strategy of short-term use of noninvasive 
vest defibrillation in high risk post MI patients, this approach 
remains to be evaluated in appropriately designed prospec-
tive trials.
There are multiple potential reasons for this lack of sur-
vival benefit with early risk stratification and ICD intervention 
in post MI patients. Implantable cardioverter defibrillators 
(ICDs) may not reduce arrhythmic death and improve total 
mortality in this patient population.7,8 It is also possible that 
the ICD therapy could demonstrate a survival benefit if risk 
stratification techniques were better able to identify patients 
at risk of arrhythmic death compared to death from causes 
other than sudden death. The ICD may decrease arrhythmic 
death but increases total mortality due to deleterious effects 
of implantation or shock therapy. These explanations are not 
mutually exclusive and multiple factors may contribute to 
lack of demonstrated benefit. Additional factors that might 
contribute to the lack of demonstrated benefit are related to 
limitations of the study designs and power. Recent autopsy 
observations, of patients experiencing sudden cardiac arrest 
in the immediate post-MI period indicate that there is a high 
frequency of cardiac rupture or recurrent MI in the first month 
after the index MI, whereas arrhythmic deaths become more 
likely subsequently.10 These findings may help to explain the 
lack of benefit of early ICD therapy after MI.6,10
Current clinical guidelines restrict ICD implants to patients 
at least 40 days after MI with continued impairment of left 
ventricular function while on optimal medical therapy.11 It is 
evident that additional research is needed with appropriately 
designed and powered studies to identify risk stratification and 
intervention strategies to prevent SCD and improve survival 
immediately after MI. In the meantime, clinicians should 
optimize and individualize therapy in the immediate post MI 
patient while carefully considering the risk of sudden death 
and the competing risk of mortality from other causes. 
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